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Abstract
Expression profiling and biomarker(s) discovery aim to provide
means for tumour diagnosis, classification, therapy response and
prognosis. The identification of novel markers could potentially lead
to the building of robust early detection strategies and persona-
lized, effective breast cancer therapies that would improve patient
outcome. Recent evidence supports the hypothesis that genomic
expression profiling using microarray analysis is a reliable method
for breast cancer classification and prognostication. However,
genes clearly do not act by themselves, or indeed they do not have
catalytic or signalling capabilities. Hence, genetic biomarker
information alone cannot perfectly predict cancer and its response
to treatment. Genes clearly exert their effect after transcription
through translation into active proteins. Consequently, postgenomic
projects correlating protein expression profiles with tumour
classification have led to some established biomarkers. In this
regard, these biomarkers associate with disease prediction and
can be associated with treatment response. Recently, Brozokova
and colleagues demonstrated that surface-enhanced laser
desorption ionization time of flight mass spectrometry (SELDI-TOF
MS) profiling of breast cancer tissue proteomes can potentially
expand the biomarker repertoire and our knowledge of breast
cancer behaviour.
New technologies for predicting or classifying cancer are
constantly evolving. Reported in this issue, a study by
Brozokova and coworkers [1] demonstrates that protein
expression profiling may enhance our accuracy of detection
and prognostication in breast cancer. It has become clear
that histological analysis is not, by itself, adequate in
predicting clinical outcome and insensitive in identifying the
optimal therapeutic strategy in many cancers [2]. Individual
tumours often carry a specific molecular footprint that may
have more in common with another tumour of different
histological type, and emphasis is now shifting toward
specific clinical management of these individual molecular
patterns rather than a blanket, ‘one size fits all’ therapy for
tumours with common histology. Breast cancer is a major
killer that remains challenging in terms of molecular
complexity and treatment response. The multifactorial nature
of breast cancer lends itself to the use of multiple biomarkers
for early detection, monitoring of response to therapy, and
clinical outcome prediction. Microarray-based gene
expression profiling has provided new insight into the
molecular intricacy of breast cancer and has provided a
clinically valuable breast cancer classification system [3-5].
However, cDNA profiles do not provide a complete picture.
After all, it is proteins in all their many post-translational coats -
and not RNA transcripts - that run the intracellular machinery.
Thus, there is a need to identify new, more accurate markers
of disease. Enter proteomic profiling.
Brozokova and colleagues [1] employed proteomics using
surface-enhanced laser desorption ionization time of flight
mass spectrometry (SELDI-TOF MS) to identify relevant
molecular signatures of breast cancer. This work revealed
subgroups of patients with differential co-expression of
protein peaks in diverse tumour subclasses, and demon-
strated differing clinicopathological characteristics in tumour
type, nuclear grade, hormonal status, mucin 1, and cyto-
keratin 5/6 or 14 between these groups. Significantly, the
patient subgroups identified by hierarchical clustering of
SELDI-TOF MS peaks were analogous to breast cancer
classifications based on gene expression profiling, classifying
the tumours into luminal, basal and HER2 subtypes [3].
Use of SELDI TOF MS has three main advantages. First, the
reliability of signatures of breast cancer gene expression is
becoming increasingly acknowledged, and proteomic profil-
ing is considered to be the final step in drawing a biological
picture of cancers. Second, despite variable biomarker
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detection from separate studies [6-10], mass spectrometry
represents an additional approach to mine novel proteins.
Third, these new biomarkers may well relate to tumour
development and behaviour extrapolated from minimal
starting material and high throughput proteomic capabilities.
A fundamental part of the study conducted by Brozokova and
colleagues was the progression from descriptive knowledge
of protein peak signature classification to the identification of
two proposed biomarkers. Here, they identified two signifi-
cant biomarkers, namely heat shock protein (HSP)27 and
annexin V, which were over-expressed in subcohorts of
patients corresponding to luminal A subtypes. Significantly,
HSP27 appears to be a bona fide biomarker, because it was
shown to be elevated in oestrogen receptor positive patients
in a previous study [11]. Further confirmation has been
reported; specifically, HSP27 and a related protein isoform of
the annexin family were found to correlate with chemo-
resistance in breast cancer [12].
Evidently, SELDI-TOF MS and mass spectrometry in general
allow a more rapid identification of many potential biomarkers
from biological samples. This study and those described
above support the use of SELDI as a complementary method
of breast cancer classification and biomarker discovery. The
identification of biomarker proteins in this work is a key
element in elucidating the relevant pathways of breast cancer,
and highlights the possibility that some of these biomarkers
may be monitored/targeted in future treatment modalities.
There are some issues regarding SELDI’s role in disease
prognosis and classification, which would benefit from larger,
multicentre validation studies. However, as mass spectro-
metry technology evolves, it is becoming increasingly clear
that changes in proteomic profiles of breast cancer will aid in
disease stratification and prognostication, and will signifi-
cantly help to guide selection of treatment regimens.
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